- Home
- ABUS vs CTO Comparison
ABUS vs CTO Comparison
Compare ABUS & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABUS | CTO |
|---|---|---|
| Founded | 2005 | 1902 |
| Country | United States | United States |
| Employees | N/A | 42 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.8M | 688.5M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABUS | CTO |
|---|---|---|
| Price | $4.28 | $20.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $22.50 |
| AVG Volume (30 Days) | ★ 1.3M | 411.0K |
| Earning Date | 05-14-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 7.44% |
| EPS Growth | ★ 55.26 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $14,083,000.00 | N/A |
| Revenue This Year | N/A | $7.63 |
| Revenue Next Year | $239.71 | $2.76 |
| P/E Ratio | $5.00 | ★ N/A |
| Revenue Growth | ★ 128.21 | N/A |
| 52 Week Low | $3.04 | $15.07 |
| 52 Week High | $5.10 | $20.93 |
Technical Indicators
Market Signals| Indicator | ABUS | CTO |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 55.53 |
| Support Level | $4.16 | $19.22 |
| Resistance Level | $4.63 | $20.83 |
| Average True Range (ATR) | 0.19 | 0.43 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 26.03 | 63.15 |
Price Performance
Historical ComparisonAbout ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.